[go: up one dir, main page]

CN102816173B - Preparation method of cefodizime sodium - Google Patents

Preparation method of cefodizime sodium Download PDF

Info

Publication number
CN102816173B
CN102816173B CN201210317362.4A CN201210317362A CN102816173B CN 102816173 B CN102816173 B CN 102816173B CN 201210317362 A CN201210317362 A CN 201210317362A CN 102816173 B CN102816173 B CN 102816173B
Authority
CN
China
Prior art keywords
sodium
compound
add
acetone
cefodizime
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201210317362.4A
Other languages
Chinese (zh)
Other versions
CN102816173A (en
Inventor
赵新祥
王玲
胡方锋
张振安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amicogen China Biopharm Co Ltd
Original Assignee
Shandong Lukang Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Lukang Pharmaceutical Co Ltd filed Critical Shandong Lukang Pharmaceutical Co Ltd
Priority to CN201210317362.4A priority Critical patent/CN102816173B/en
Publication of CN102816173A publication Critical patent/CN102816173A/en
Application granted granted Critical
Publication of CN102816173B publication Critical patent/CN102816173B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Cephalosporin Compounds (AREA)

Abstract

The invention relates to a preparation method of cefodizime sodium. By the preparation method, GCLE substitutes for traditional 7-ACA (7-Aminocephalosporanic acid) as starting materials to synthesize the cefodizime sodium, and after decoloration, reaction liquor is not subjected to separation and purification but is directly dropwise added with salt-forming agents for reaction so that the cefodizime sodium is obtained. The preparation method is short in step and less in side reaction, solves the problem of high superpolymer content of a final product and enables the superpolymer content to be decreased from 1.0% to smaller than 0.1%, product purity is improved and is above 99.8%, and product yield is improved and is above 90% by the aid of the raw material ratio and mixed solvent. Additionally, the preparation method is shorter in process step, timesaving, simple in process, high in yield and product purity, low in cost, cheap and available in raw materials and suitable for industrial production.

Description

一种头孢地嗪钠的制备方法A kind of preparation method of cefodizime sodium

技术领域 technical field

本发明属于化学药物合成领域,具体涉及一种以GCLE为起始原料制备头孢地嗪钠的方法。 The invention belongs to the field of chemical drug synthesis, and in particular relates to a method for preparing cefodizime sodium by using GCLE as a starting material.

背景技术 Background technique

头孢地嗪钠,又名头孢地嗪,英文名称为Cefodizime Sodium,其化学名称为:(6R,7R)-7-[(2-氨基-4-噻唑基)-(甲氧亚氨基)乙酰胺基]-3-[[(5-羧甲基-4-甲基-2-噻唑基)硫]甲基]-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-甲酸二钠盐,分子式:C20H18N6O7S4Na2,分子量:628.64,结构式如化合物Ⅴ所示:  Cefodizime sodium, also known as cefodizime, the English name is Cefodizime Sodium, and its chemical name is: (6R,7R)-7-[(2-amino-4-thiazolyl)-(methoxyimino)acetamide Base]-3-[[(5-carboxymethyl-4-methyl-2-thiazolyl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0] Oct-2-ene-2-carboxylic acid disodium salt, molecular formula: C 20 H 18 N 6 O 7 S 4 Na 2 , molecular weight: 628.64, structural formula as shown in compound V:

头孢地嗪钠属于第三代注射用头孢菌素类抗生素,由德国赫斯特公司开发,主要用于治疗急性细菌感染性疾病,下呼吸道感染、泌尿系统感染等疾病,同时对提高人体免疫调节能力有一定的作用。 Cefodizime sodium belongs to the third generation of cephalosporin antibiotics for injection, which was developed by Hearst Company in Germany. Ability plays a role.

目前,现有技术中制备头孢地嗪钠都是以7-ACA或者是以7-ACA的后续产物头孢噻肟酸为原料,反应过程中容易产生副产物,影响产品质量,纯度不高;采用7-ACA为原料制备头孢地嗪钠存在得率低,质量欠佳,且反应时间长,不利于连续性、大规模工业化生产。因此,研究开发工艺简单、高得率,高质量,并适合于大规模工业化生产的合成技术,已成为当务之急。 At present, the preparation of cefodizime sodium in the prior art all takes 7-ACA or the follow-up product cefotaxime acid of 7-ACA as raw material, easily produces by-products in the reaction process, affects product quality, and the purity is not high; 7-ACA is used as raw material to prepare cefodizime sodium with low yield, poor quality and long reaction time, which is not conducive to continuous and large-scale industrial production. Therefore, research and development of synthetic techniques with simple process, high yield, high quality, and suitable for large-scale industrial production have become a top priority.

头孢地嗪钠主要由头孢地嗪酸制备,在制备过程中重要的就是头孢地嗪酸的溶解。美国专利US5126445公开了将头孢地嗪酸混悬于水中,滴加三乙胺溶解,向澄清溶液中滴加异辛酸钠溶液析出头孢地嗪钠,所得产品颜色较深,需要进行精制,影响产品质量和收率。美国专利US4590267公开了将头孢地嗪钠用碳酸氢钠溶解,滴加醇析出头孢地嗪钠,以碳酸氢钠溶解,溶解时间长,而且所得产品中易包含未溶解的碳酸氢钠,影响产品质量。中国专利CN101239985公开了将头孢地嗪酸混悬于两相体系中,加入异辛酸钠搅拌全溶,分层,水层加入醇析出头孢地嗪钠,其两相体系选自二氯甲烷/水、四氯甲烷/水、甲苯/水或乙酸乙酯/水,该方法中用到大量的有机溶剂,而且回收率低,污染环境,成本较高,操作步骤多而复杂,而且产品纯度较低。中国专利CN101723958B公开了将头孢地嗪酸混悬于乙醇中,滴加三乙胺溶解,脱色,向澄清溶液中滴加异辛酸钠的乙醇溶液析晶,抽滤,用无水乙醇和丙酮洗涤,干燥,得到头孢地嗪钠,该方法中用到大量的乙醇,生产成本较高,操作步骤多而复杂。 Cefodizime sodium is mainly prepared from cefodizime acid, and the most important thing in the preparation process is the dissolution of cefodizime acid. U.S. Patent No. 5,126,445 discloses suspending cefodizime acid in water, adding triethylamine dropwise to dissolve it, and adding sodium isooctanoate solution dropwise to the clear solution to precipitate cefodizime sodium. The resulting product has a darker color and needs to be refined, which affects the product quality and yield. U.S. Patent No. 4,590,267 discloses dissolving cefodizime sodium with sodium bicarbonate, adding alcohol dropwise to separate out cefodizime sodium, and dissolving it with sodium bicarbonate. The dissolution time is long, and the resulting product easily contains undissolved sodium bicarbonate, which affects the product. quality. Chinese patent CN101239985 discloses suspending cefodizime acid in a two-phase system, adding sodium isooctanoate and stirring to completely dissolve, layering, adding alcohol to the water layer to precipitate cefodizime sodium, and the two-phase system is selected from dichloromethane/water , tetrachloromethane/water, toluene/water or ethyl acetate/water, a large amount of organic solvents are used in this method, and the recovery rate is low, pollutes the environment, the cost is higher, the operation steps are many and complicated, and the product purity is lower . Chinese patent CN101723958B discloses suspending cefodizime acid in ethanol, adding dropwise triethylamine to dissolve, decolorizing, adding dropwise ethanol solution crystallization of sodium isooctanoate to the clear solution, suction filtration, and washing with absolute ethanol and acetone , dry to obtain cefodizime sodium, a large amount of ethanol is used in this method, the production cost is higher, and the operation steps are many and complicated.

发明内容 Contents of the invention

在本发明中,为了叙述方便,将GCLE,即7-苯乙酰胺基-3-氯甲基头孢烷酸对甲氧基苄酯,简称为化合物Ⅰ;甲巯基噻唑乙酸简称为化合物Ⅱ;(6R,7R)-7-胺基]-3-[[(5-羧甲基-4-甲基-2-噻唑基)硫]甲基]-8-氧代-5-硫杂-1-氮杂双环(4.2.0)辛-2-烯-2-甲酸简称为化合物Ⅲ;AE活性酯简称为化合物Ⅳ;头孢地嗪钠简称为化合物Ⅴ。 In the present invention, for convenience of description, GCLE, that is, 7-phenylacetamido-3-chloromethyl cephalosporanic acid p-methoxybenzyl ester, is referred to as compound I for short; Methylmercaptothiazole acetic acid is referred to as compound II for short; ( 6R,7R)-7-amino]-3-[[(5-carboxymethyl-4-methyl-2-thiazolyl)thio]methyl]-8-oxo-5-thia-1- Azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid is referred to as compound Ⅲ; AE active ester is referred to as compound Ⅳ; cefodizime sodium is referred to as compound Ⅴ.

针对现有技术的不足之处,本发明的目的在于提供一种以GCLE代替传统的7-ACA为起始原料制备头孢地嗪钠的方法,用GCLE两步合成头孢地嗪钠,解决了现有技术中高聚物含量高的问题,该合成反应步骤短,副反应少,操作简单,收率高,所得产品纯度高。 For the deficiencies in the prior art, the object of the present invention is to provide a kind of method that replaces traditional 7-ACA with GCLE as starting material to prepare cefodizime sodium, and synthesize cefodizime sodium in two steps with GCLE, which solves the existing problem There is the problem of high polymer content in the technology, the synthesis reaction steps are short, the side reactions are few, the operation is simple, the yield is high, and the obtained product has high purity.

一种头孢地嗪钠的制备方法,采用化合物Ⅰ为起始原料,具体步骤包括: A preparation method of cefodizime sodium, using compound I as a starting material, the specific steps comprising:

(1)将化合物Ⅰ和化合物Ⅱ混悬于含有机溶剂的水溶液中,加热到50℃,搅拌至澄清,加入催化剂,用质量分数为8%-12%的碳酸氢钠溶液或碳酸钠溶液调pH 5.0-5.5,反应1-2小时,加卤代酸水解后,再加活性炭脱色,洗涤,用质量分数为25%-28%的氨水调pH 2.5-3.5,养晶,抽滤,洗涤,真空干燥,得到浅黄色或类白色结晶性粉末,即化合物Ⅲ; (1) Suspend compound I and compound II in an aqueous solution containing an organic solvent, heat to 50°C, stir until clarification, add a catalyst, and adjust with a sodium bicarbonate solution or sodium carbonate solution with a mass fraction of 8%-12%. pH 5.0-5.5, react for 1-2 hours, add halogenated acid for hydrolysis, add activated carbon for decolorization, wash, adjust pH to 2.5-3.5 with ammonia water with a mass fraction of 25%-28%, grow crystals, suction filter, wash, Vacuum drying to obtain light yellow or off-white crystalline powder, namely compound III;

(2)在混合溶媒中,将化合物Ⅲ和化合物Ⅳ加入后搅拌,然后滴加有机碱反应1-2小时,加活性炭脱色,过滤,洗涤,滴加成盐剂溶液,慢慢搅拌至浑浊出晶,养晶,抽滤,洗涤,真空干燥,得到白色或类白色化合物Ⅴ,即头孢地嗪钠。 (2) In the mixed solvent, add compound III and compound IV and stir, then dropwise add organic base to react for 1-2 hours, add activated carbon to decolorize, filter, wash, add dropwise salt-forming agent solution, stir slowly until turbidity comes out crystallization, crystal growth, suction filtration, washing, and vacuum drying to obtain white or off-white compound V, namely cefodizime sodium.

合成路线为: The synthetic route is:

 其中,步骤(1)中所述的催化剂为金属溴化物或金属碘化物,优选为碘化钠,碘化钠参加卤代反应比较容易,用量小且反应彻底,效果较好;步骤(1)中所述的卤代酸是三氟乙酸。 Wherein, the catalyst described in step (1) is metal bromide or metal iodide, preferably sodium iodide, sodium iodide is relatively easy to participate in the halogenation reaction, the dosage is small and the reaction is thorough, and the effect is better; step (1) The halogenated acid described in is trifluoroacetic acid.

所述步骤(1)中化合物Ⅰ与化合物Ⅱ的质量比为1:0.41-0.47,由于化合Ⅰ比化合物Ⅱ成本高,所以此配比范围能够保证高成本的化合物Ⅰ反应完全;化合物Ⅰ与催化剂的质量比为1:0.01-0.03,高于此配比范围,反应不彻底,残留高,低于此配比范围,产品的颜色较重,同时造成催化剂的浪费;化合物Ⅰ与卤代酸的质量比为1:1.8-4.7,在此配比范围能够保证化合物Ⅰ中的4位保护基羧基的完全脱除,否则4位保护基不能完全脱除,增加产品中的杂质,或者造成原料的浪费。 In the step (1), the mass ratio of compound I to compound II is 1:0.41-0.47. Since compound I is more costly than compound II, this ratio range can ensure that the high-cost compound I reacts completely; compound I and the catalyst The mass ratio is 1:0.01-0.03. If it is higher than this ratio range, the reaction will be incomplete and the residue will be high. If it is lower than this ratio range, the color of the product will be heavier, and it will cause waste of catalyst; compound I and halogenated acid The mass ratio is 1:1.8-4.7, and this ratio range can ensure the complete removal of the 4-position protecting group carboxyl group in compound I, otherwise the 4-position protecting group cannot be completely removed, increasing impurities in the product, or causing waste.

步骤(1)中所述的有机溶剂为丙酮,所述的含有机溶剂的水溶液中丙酮与水的体积比为20:1-2,在此比例范围内反应比较彻底,收率高,同时产品的颜色较好。 The organic solvent described in the step (1) is acetone, and the volume ratio of acetone and water in the aqueous solution containing the organic solvent is 20:1-2, and the reaction is relatively thorough within this ratio range, and the yield is high, and the product The color is better.

步骤(2)中所述的化合物Ⅲ与化合物Ⅳ的质量比为1:1.37-1.71,高于于此比例范围,导致化合物Ⅲ反应不完全,杂质升高;低于此比列,造成化合物Ⅳ的浪费,同时后处理也比较麻烦。 The mass ratio of compound III to compound IV described in step (2) is 1:1.37-1.71, higher than this ratio range, resulting in incomplete reaction of compound III and increased impurities; lower than this ratio, resulting in compound IV waste, and post-processing is also more troublesome.

步骤(2)中所述的混合溶媒为丙酮或甲苯和醇组成的溶剂,所述的醇为乙醇;所述的混合溶媒优选为丙酮和乙醇组成的溶剂,丙酮和乙醇的体积比为1-3:1。混合溶媒的作用是降低头孢地嗪钠的溶解度,提高收率,而且对于极性小的杂质有很好的去除作用,提高了产品的纯度。此比例范围是最佳溶媒量,不但对所生成钠盐的溶解性小,收率高,而且产品的晶型为规则的棒状晶型,容易干燥,容易分装。 The mixed solvent described in step (2) is a solvent composed of acetone or toluene and alcohol, and the alcohol is ethanol; the mixed solvent is preferably a solvent composed of acetone and ethanol, and the volume ratio of acetone and ethanol is 1- 3:1. The role of the mixed solvent is to reduce the solubility of cefodizime sodium, improve the yield, and have a good removal effect on impurities with low polarity, thereby improving the purity of the product. This ratio range is the optimum solvent amount, not only has low solubility to the generated sodium salt, but also has a high yield, and the crystal form of the product is a regular rod-shaped crystal form, which is easy to dry and pack.

步骤(2)中所述的有机碱为吡啶或三乙胺或二乙胺或叔丁胺或苯胺或吗啉的一种,优选三乙胺。所述有机碱的主要作用是溶解及催化的作用,但是从产品的收率和颜色上看,从碱性大小上考虑三乙胺的效果比较温和。 The organic base described in step (2) is one of pyridine or triethylamine or diethylamine or tert-butylamine or aniline or morpholine, preferably triethylamine. The main function of the organic base is dissolution and catalysis, but from the yield and color of the product, the effect of triethylamine is milder in terms of alkalinity.

步骤(2)中所述的成盐剂为异辛酸钠或甲醇钠或醋酸钠中的一种,化合物Ⅲ与成盐剂的质量比为1:0.15-0.95,所述成盐剂用量过少,成盐不彻底,影响产品收率,成盐剂用量过大,有机酸残留高,导致过敏现象。其中所述的成盐剂优选异辛酸钠,这是因为异辛酸钠在有机溶媒中的溶解性比较大,并且生成的副产物有机酸也比较容易去除。 The salt-forming agent described in step (2) is one of sodium isooctanoate, sodium methoxide or sodium acetate, the mass ratio of compound III to the salt-forming agent is 1:0.15-0.95, and the amount of the salt-forming agent is too small , The salt formation is not complete, which affects the product yield. The dosage of the salt formation agent is too large, and the residual organic acid is high, leading to allergies. The salt-forming agent described therein is preferably sodium isooctanoate, and this is because the solubility of sodium isooctanoate in an organic solvent is relatively large, and the by-product organic acid generated is also relatively easy to remove.

所述步骤(1)和步骤(2)中养晶过程的温度范围为10℃-15℃,养晶时间为1小时。 The temperature range of the crystal growing process in the step (1) and the step (2) is 10°C-15°C, and the crystal growing time is 1 hour.

所述步骤(2)中的成盐剂溶液是将成盐剂溶于混合溶媒中形成的溶液。所述步骤(2)在混合溶媒中,将化合物Ⅲ和化合物Ⅳ加入后搅拌,然后滴加有机碱反应1-2小时,加活性炭脱色,过滤,洗涤;将成盐剂溶于混合溶媒中进行滴加,慢慢搅拌至浑浊出晶,为了析出更多晶体再滴加丙酮或甲苯,养晶,抽滤,洗涤,真空干燥得到白色或类白色化合物Ⅴ,即头孢地嗪钠。 The salt-forming agent solution in the step (2) is a solution formed by dissolving the salt-forming agent in a mixed solvent. In the step (2), in the mixed solvent, add compound III and compound IV and stir, then dropwise add an organic base to react for 1-2 hours, add activated carbon for decolorization, filter, and wash; dissolve the salt-forming agent in the mixed solvent for dripping Add, slowly stir until turbid and crystallize, in order to precipitate more crystals, add acetone or toluene dropwise, grow the crystals, filter with suction, wash, and dry in vacuo to obtain white or off-white compound V, namely cefodizime sodium.

GCLE,即7-苯乙酰胺基-3-氯甲基头孢烷酸对甲氧基苄酯,是继7-ACA、7-ADCA(7-氨基-3-去乙酰氧基头孢烷酸)之后的又一合成头孢类药物母核,可代替7-ACA用于制备的头孢菌素,其C-3位为-CH2Cl,可以以此为先导化合物,制得C-3位含双键、硫甲基、氮甲基等的一系列头孢类药物。其C-3上的氯增加了反应活性,且C-4位羧基、C-7位氨基已被保护,在C-3位反应时可减少副反应发生,所得产品纯度高,外观颜色好。以GCLE为母核生产头孢菌素时,产品收率更高、生产工艺更简单、生产条件更温和、产品成本更低。GCLE以价格低廉的青霉素G钾盐为起始原料制备,产品成本低,价格仅为7-ACA价格的60%左右。GCLE由日本大冢化学株式会社最早研制生产,至今已有十几年的历史,近年来国内GCLE的合成生产技术已经非常成熟,加上国内青霉素产能的不断扩张和发酵技术方面的较大优势,GCLE价格大幅度下降,目前不仅供应国内使用,还大量出口,GCLE合成头孢类药物显示出较强的质量和成本优势。 GCLE, namely 7-phenylacetamido-3-chloromethyl cephalosporanic acid p-methoxybenzyl ester, is following 7-ACA, 7-ADCA (7-amino-3-desacetoxy cephalosporanic acid) Another synthetic cephalosporin drug nucleus, which can replace 7-ACA for the preparation of cephalosporins, its C-3 position is -CH 2 Cl, which can be used as a lead compound to prepare a C-3 position containing a double bond A series of cephalosporins such as thiomethyl, nitrogen methyl, etc. The chlorine on the C-3 increases the reactivity, and the carboxyl group at the C-4 position and the amino group at the C-7 position have been protected, which can reduce the occurrence of side reactions when reacting at the C-3 position, and the obtained product has high purity and good appearance color. When GCLE is used as the mother nucleus to produce cephalosporins, the product yield is higher, the production process is simpler, the production conditions are milder, and the product cost is lower. GCLE is prepared from the cheap penicillin G potassium salt as the starting material, and the product cost is low, and the price is only about 60% of the price of 7-ACA. GCLE was first developed and produced by Japan's Otsuka Chemical Co., Ltd., and has a history of more than ten years. In recent years, the synthesis and production technology of GCLE in China has been very mature, coupled with the continuous expansion of domestic penicillin production capacity and great advantages in fermentation technology, The price of GCLE has dropped significantly. At present, it is not only supplied for domestic use, but also exported in large quantities. GCLE's synthetic cephalosporins have shown strong advantages in quality and cost.

本发明与现有技术相比,其有益效果是: The present invention compares with prior art, and its beneficial effect is:

一、以GCLE代替传统的7-ACA为起始原料合成头孢地嗪钠,产品收率更高、生产工艺更简单、生产条件更温和、产品成本更低。由于化学法制备7-ACA成本太高,很难购买到,而酶法制备7-ACA蛋白质含量高,导致最终产品高聚物含量高,用药时过敏几率大,本发明所述头孢地嗪钠的制备方法解决了最终产品高聚物含量高的问题,高聚物含量从1.0%降低到0.1%以下,同时提高了纯度,纯度为99.8%以上;  1. Using GCLE instead of traditional 7-ACA as the starting material to synthesize cefodizime sodium, the product yield is higher, the production process is simpler, the production conditions are milder, and the product cost is lower. Because the cost of preparing 7-ACA by chemical method is too high, it is difficult to buy, and the protein content of 7-ACA prepared by enzymatic method is high, resulting in high polymer content of the final product, and the probability of allergies during medication is large. Cefodizime sodium according to the present invention The preparation method solves the problem of high polymer content in the final product, the high polymer content is reduced from 1.0% to less than 0.1%, and the purity is improved at the same time, the purity is above 99.8%;

二、在混合溶媒中,化合物Ⅲ和化合物Ⅳ加有机碱反应生成头孢地嗪酸,加入活性炭进行脱色,脱色后的反应液不经分离纯化步骤,把成盐剂溶解在混合溶媒中,直接滴加成盐剂溶液反应生成头孢地嗪钠,所述混合溶媒的使用降低了头孢地嗪钠的溶解度,提高了收率,而且对于小极性的杂质有很好的去除作用,提高了产品的纯度;而现有技术中合成的中间体头孢地嗪酸需经过结晶、洗涤和干燥工艺步骤,在与成盐剂反应中还需要再次加溶剂进行溶解。本发明中步骤(2)在混合溶媒中完成,省去了中间的分离步骤,缩短了工艺步骤,节省了时间;本发明中所述的原料配比和混合溶媒的使用,提高了收率,使得产品收率达90%以上。 2. In the mixed solvent, compound III and compound IV are reacted with an organic base to generate cefodizime acid, and activated carbon is added for decolorization. The decolorized reaction solution is not subjected to separation and purification steps, and the salt-forming agent is dissolved in the mixed solvent and dripped directly The salt addition solution reacts to generate cefodizime sodium, the use of the mixed solvent reduces the solubility of cefodizime sodium, improves the yield, and has a good removal effect for small polar impurities, which improves the product quality. Purity; and the intermediate cefodizime acid synthesized in the prior art needs to go through the process steps of crystallization, washing and drying, and also needs to add solvent again to dissolve in the reaction with the salt-forming agent. In the present invention, step (2) is completed in the mixed solvent, which saves the intermediate separation steps, shortens the process steps, and saves time; the raw material ratio and the use of the mixed solvent described in the present invention improve the yield, Make the product yield reach more than 90%.

本发明提供的头孢地嗪钠的制备方法,步骤短,副反应少,解决了最终产品高聚物含量高的问题,高聚物含量从1.0%降低到0.1%以下,而且提高了纯度,产品纯度为99.8%以上,所述的原料配比和混合溶媒的使用,提高了收率,使得产品收率达90%以上。本发明缩短了工艺步骤,节省了时间,工艺简单,收率高,成本低,产品纯度高,原料廉价易得,适合工业化生产。 The preparation method of cefodizime sodium provided by the invention has short steps and few side reactions, solves the problem of high polymer content in the final product, reduces the high polymer content from 1.0% to below 0.1%, and improves the purity, the product The purity is more than 99.8%. The ratio of the raw materials and the use of the mixed solvent have improved the yield, so that the product yield can reach more than 90%. The invention shortens the process steps, saves time, has simple process, high yield, low cost, high product purity, cheap and easy-to-obtain raw materials, and is suitable for industrialized production.

附图说明 Description of drawings

附图1为本发明实施例1头孢地嗪钠HPLC图谱;                 Accompanying drawing 1 is the HPLC collection of illustrative plates of cefodizime sodium of embodiment 1 of the present invention;

附图2为本发明实施例2头孢地嗪钠HPLC图谱; Accompanying drawing 2 is the HPLC collection of illustrative plates of embodiment of the present invention 2 cefodizime sodium;

附图3为本发明实施例3头孢地嗪钠HPLC图谱; Accompanying drawing 3 is the HPLC collection of illustrative plates of embodiment of the present invention 3 cefodizime sodium;

附图4为本发明实施例4头孢地嗪钠HPLC图谱。 Accompanying drawing 4 is the HPLC spectrum of cefodizime sodium of embodiment 4 of the present invention.

具体实施方式 Detailed ways

下面结合实施例对本发明做进一步说明,所述仅为本发明的若干个具体实施形式,对于本领域的普通技术人员来说,还可以做出许多变形与改进。所有未超出权利要求所述的变形或改进均应视为本发明的范围。 The present invention will be further described below in conjunction with the embodiments, which are only several specific implementation forms of the present invention, and many variations and improvements can be made by those skilled in the art. All modifications or improvements that do not exceed the scope of the claims should be regarded as the scope of the present invention.

实施例1 Example 1

头孢地嗪钠的制备方法,采用化合物Ⅰ为起始原料,具体步骤包括:  The preparation method of cefodizime sodium adopts compound I as a starting material, and the specific steps include:

(1)将化合物Ⅰ(GCLE)30g和化合物Ⅱ12.3g加入含有200mL丙酮和20mL水的体系中,加热到50℃,搅拌至澄清,加碘化钠0.3g,用质量分数为10%碳酸钠溶液调pH为5.0,反应2小时,加100g三氟乙酸水解后,加活性炭1.5g脱色,采用10mL丙酮和1mL水混合液洗涤,用质量分数为25%的氨水调pH至3.0,10℃养晶1小时,抽滤,100mL水和100mL丙酮分别洗涤,真空干燥,得22.1g化合物Ⅲ,收率为92%,纯度为98.76%; (1) Add 30g of compound I (GCLE) and 12.3g of compound II into a system containing 200mL of acetone and 20mL of water, heat to 50°C, stir until clear, add 0.3g of sodium iodide, and use a mass fraction of 10% sodium carbonate Adjust the pH of the solution to 5.0, react for 2 hours, add 100 g of trifluoroacetic acid for hydrolysis, add 1.5 g of activated carbon for decolorization, wash with a mixture of 10 mL of acetone and 1 mL of water, adjust the pH to 3.0 with 25% ammonia water, and culture at 10 °C. crystallize for 1 hour, filter with suction, wash with 100mL of water and 100mL of acetone respectively, and dry in vacuo to obtain 22.1g of compound III with a yield of 92% and a purity of 98.76%;

(2)将化合物Ⅲ 20g和化合物Ⅳ27.4g加入含有100mL甲苯和100mL甲醇的混合溶媒体系中,滴加三乙胺23mL,5℃反应1.5hr,加1g活性炭脱色,过滤,5mL甲苯和5mL甲醇混合液洗涤,备用; (2) Add 20g of compound III and 27.4g of compound IV into a mixed solvent system containing 100mL of toluene and 100mL of methanol, dropwise add 23mL of triethylamine, react at 5°C for 1.5hr, add 1g of activated carbon for decolorization, filter, 5mL of toluene and 5mL of methanol Wash the mixture and set aside;

将异辛酸钠19g溶于25mL甲苯和25mL甲醇的混合溶液中,慢慢滴入上述备用反应液中,慢慢搅拌至浑浊出晶,滴加甲苯100mL,10℃养晶1小时,抽滤,50mL甲苯洗涤,真空干燥,得28.5g化合物Ⅴ,收率为91%,纯度为99.84%,高聚物含量为0.083%。 Dissolve 19g of sodium isooctanoate in a mixed solution of 25mL of toluene and 25mL of methanol, slowly drop it into the above-mentioned standby reaction solution, stir slowly until turbid and crystallize, add dropwise 100mL of toluene, grow crystals at 10°C for 1 hour, and filter with suction. After washing with 50 mL of toluene and drying in vacuo, 28.5 g of compound V was obtained with a yield of 91%, a purity of 99.84%, and a high polymer content of 0.083%.

实施例2   Example 2

头孢地嗪钠的制备方法,采用化合物Ⅰ为起始原料,具体步骤包括: The preparation method of cefodizime sodium adopts compound I as a starting material, and the specific steps include:

(1)将化合物Ⅰ(GCLE)30g和化合物Ⅱ13.2g加入含有200mL丙酮和15mL水的体系中,加热到50℃,搅拌至澄清,加溴化钠0.7g,用质量分数为8%碳酸氢钠溶液调节pH 至5.5,反应1小时,加141g三氟乙酸水解后,加活性炭1.5g脱色,10mL丙酮和0.75mL水混合液洗涤,用质量分数为28%的氨水调pH 为3.5,12℃养晶1小时,抽滤,100mL水和100mL丙酮分别洗涤,真空干燥,得21.8g化合物Ⅲ,收率为91%,纯度为98.62%; (1) Add 30g of compound I (GCLE) and 13.2g of compound II into a system containing 200mL of acetone and 15mL of water, heat to 50°C, stir until clear, add 0.7g of sodium bromide, and use a mass fraction of 8% bicarbonate Adjust the pH to 5.5 with sodium solution, react for 1 hour, add 141g of trifluoroacetic acid for hydrolysis, add 1.5g of activated carbon for decolorization, wash with a mixture of 10mL of acetone and 0.75mL of water, adjust the pH to 3.5 with 28% ammonia water, 12°C Cultivate the crystal for 1 hour, filter with suction, wash with 100 mL of water and 100 mL of acetone respectively, and dry in vacuo to obtain 21.8 g of compound III with a yield of 91% and a purity of 98.62%;

(2)将化合物Ⅲ 20g和化合物Ⅳ34.2g加入含有200mL甲苯和100mL乙醇的混合溶媒体系中,滴加二乙胺23mL,10℃反应1.5hr,加1g活性炭脱色,过滤,10mL甲苯和5mL乙醇混合液洗涤,备用; (2) Add 20g of compound III and 34.2g of compound IV into a mixed solvent system containing 200mL of toluene and 100mL of ethanol, add dropwise 23mL of diethylamine, react at 10°C for 1.5hr, add 1g of activated carbon for decolorization, filter, 10mL of toluene and 5mL of ethanol Wash the mixture and set aside;

将甲醇钠3g溶于50mL甲苯和25mL乙醇的混合溶液中,慢慢滴入上述备用反应液中,慢慢搅拌至浑浊出晶,滴加甲苯100mL,12℃养晶1小时,抽滤,50mL甲苯洗涤,真空干燥,得28.2g化合物Ⅴ,收率为90%,纯度为99.80%,高聚物含量为0.09%。 Dissolve 3g of sodium methoxide in a mixed solution of 50mL of toluene and 25mL of ethanol, slowly drop it into the above-mentioned standby reaction solution, stir slowly until turbid and crystallize, add dropwise 100mL of toluene, grow crystals at 12°C for 1 hour, filter with suction, 50mL After washing with toluene and vacuum drying, 28.2 g of compound V was obtained, with a yield of 90%, a purity of 99.80%, and a high polymer content of 0.09%.

实施例3    Example 3

头孢地嗪钠的制备方法,采用化合物Ⅰ为起始原料,具体步骤包括: The preparation method of cefodizime sodium adopts compound I as a starting material, and the specific steps include:

(1)将化合物Ⅰ(GCLE)30g和化合物Ⅱ14.1g加入含有200mL丙酮和10mL水的体系中,加热到50℃,搅拌至澄清,加溴化钾0.9g,用质量分数为12%的碳酸氢钠溶液调节pH至 5.2,反应2小时,加三氟乙酸54g水解后,加活性炭1.5g脱色,10mL丙酮和1mL水混合液洗涤,用质量分数为26%的氨水调pH至 3.5,15℃养晶1小时,抽滤,100mL水和100mL丙酮分别洗涤,真空干燥,得21.5g化合物Ⅲ,收率为90%,纯度为98.56%; (1) Add 30g of compound I (GCLE) and 14.1g of compound II into a system containing 200mL of acetone and 10mL of water, heat to 50°C, stir until clear, add 0.9g of potassium bromide, and use 12% carbonic acid Adjust the pH to 5.2 with sodium hydrogen solution, react for 2 hours, add 54g of trifluoroacetic acid for hydrolysis, add 1.5g of activated carbon for decolorization, wash with 10mL of acetone and 1mL of water mixture, adjust the pH to 3.5 with 26% ammonia water, 15°C Cultivate the crystal for 1 hour, filter with suction, wash with 100 mL of water and 100 mL of acetone respectively, and dry in vacuo to obtain 21.5 g of compound III with a yield of 90% and a purity of 98.56%;

(2)将化合物Ⅲ 20g和化合物Ⅳ30g加入含有100mL丙酮和100mL甲醇的混合溶媒体系中,滴加叔丁胺23mL,6℃反应1.5hr,加1g活性炭脱色过滤,5mL丙酮和5mL甲醇混合液洗涤,备用; (2) Add 20g of compound III and 30g of compound IV into a mixed solvent system containing 100mL of acetone and 100mL of methanol, dropwise add 23mL of tert-butylamine, react at 6°C for 1.5hr, add 1g of activated carbon for decolorization and filtration, wash with a mixture of 5mL of acetone and 5mL of methanol, and set aside ;

将醋酸钠10g溶于25mL丙酮和25mL甲醇的混合溶液中,慢慢滴入上述备用反应液中,慢慢搅拌至浑浊出晶,滴加丙酮100mL, 15℃养晶1小时,抽滤,50mL丙酮洗涤,真空干燥,得28.4g化合物Ⅴ,收率为90.6%,纯度为99.86%,高聚物含量为0.08%。 Dissolve 10g of sodium acetate in a mixed solution of 25mL of acetone and 25mL of methanol, slowly drop it into the above-mentioned standby reaction solution, stir slowly until turbid and crystallize, add dropwise 100mL of acetone, grow the crystal at 15°C for 1 hour, suction filter, 50mL After washing with acetone and vacuum drying, 28.4 g of compound V was obtained, with a yield of 90.6%, a purity of 99.86%, and a high polymer content of 0.08%.

实施例4  Example 4

头孢地嗪钠的制备方法,采用化合物Ⅰ为起始原料,具体步骤包括: The preparation method of cefodizime sodium adopts compound I as a starting material, and the specific steps include:

(1)将化合物Ⅰ(GCLE)30g和化合物Ⅱ13g加入含有200mL丙酮和20mL水的体系中,加热到50℃,搅拌至澄清,加0.7g碘化钾,用质量分数为9%的碳酸氢钠溶液调节pH至 5.3,反应2小时,加100g三氟乙酸水解后,加活性炭1.5g脱色,10mL丙酮和1mL水混合液洗涤,用质量分数为27%的氨水调pH 至2.5,13℃养晶1小时,抽滤,100mL水和100mL丙酮分别洗涤,真空干燥,得21.7g化合物Ⅲ,收率为91.5%,纯度为98.60%; (1) Add 30g of compound I (GCLE) and 13g of compound II into a system containing 200mL of acetone and 20mL of water, heat to 50°C, stir until clear, add 0.7g of potassium iodide, and adjust with 9% sodium bicarbonate solution pH to 5.3, react for 2 hours, add 100g of trifluoroacetic acid for hydrolysis, add 1.5g of activated carbon for decolorization, wash with 10mL of acetone and 1mL of water mixture, adjust the pH to 2.5 with 27% ammonia water, grow crystals at 13°C for 1 hour , filtered with suction, washed with 100mL of water and 100mL of acetone respectively, and dried in vacuo to obtain 21.7g of compound III with a yield of 91.5% and a purity of 98.60%;

(2)将化合物Ⅲ 20g和化合物Ⅳ30g加入含有100mL丙酮和100mL乙醇的混合溶媒体系中,滴加吡啶23mL,8℃反应1.5小时,加1g活性炭脱色,过滤,5mL丙酮和5mL乙醇洗涤,备用; (2) Add 20g of compound III and 30g of compound IV into a mixed solvent system containing 100mL of acetone and 100mL of ethanol, add dropwise 23mL of pyridine, react at 8°C for 1.5 hours, add 1g of activated carbon for decolorization, filter, wash with 5mL of acetone and 5mL of ethanol, and set aside;

将异辛酸钠10g溶于25mL丙酮和25mL乙醇的混合溶液中,慢慢滴入上述备用反应液中,慢慢搅拌至浑浊出晶,滴加丙酮100mL,13℃养晶1小时,抽滤,50mL丙酮洗涤,真空干燥,得28.2g化合物Ⅴ,收率为90%,纯度为99.82%,高聚物含量为0.09%。 Dissolve 10 g of sodium isooctanoate in a mixed solution of 25 mL of acetone and 25 mL of ethanol, slowly drop it into the above-mentioned standby reaction solution, stir slowly until turbid and crystallize, add dropwise 100 mL of acetone, grow crystals at 13°C for 1 hour, and filter with suction. After washing with 50 mL of acetone and drying in vacuum, 28.2 g of compound V was obtained with a yield of 90%, a purity of 99.82%, and a high polymer content of 0.09%.

根据实施例1-4可以看出,本发明提供的头孢地嗪钠的制备方法,步骤短,副反应少,解决了最终产品高聚物含量高的问题,高聚物含量在0.1%以下,产品纯度为99.8%以上,产品收率达90%以上;本发明缩短了工艺步骤,节省了时间,工艺简单,收率高,成本低,产品纯度高,原辅料廉价易得,适合工业化生产。 Can find out according to embodiment 1-4, the preparation method of cefodizime sodium provided by the present invention, step is short, and side reaction is few, has solved the problem that final product high polymer content is high, and high polymer content is below 0.1%, The product purity is more than 99.8%, and the product yield is more than 90%. The invention shortens the process steps, saves time, has simple process, high yield, low cost, high product purity, cheap and easy-to-obtain raw and auxiliary materials, and is suitable for industrial production.

Claims (1)

1. a preparation method for Cefodizime Sodium, is characterized in that: employing chemical compounds I is starting raw material, and concrete steps comprise:
(1) chemical compounds I and compound ii are suspended in the aqueous solution containing organic solvent, are heated to 50 ℃, stir to clarify, add catalyzer, the sodium hydrogen carbonate solution that is 8%-12% with massfraction or sodium carbonate solution are adjusted pH to 5.0-5.5, reaction 1-2 hour, add after halogenated acid hydrolysis, then add activated carbon decolorizing, washing, the ammoniacal liquor that is 25%-28% with massfraction is adjusted pH to 2.5-3.5, growing the grain, suction filtration, washing, vacuum-drying, obtains light yellow or off-white color crystalline powder, i.e. compound III;
(2) in mixed solvent, compound III and compounds Ⅳ are added to rear stirring, then drip organic bases reaction 1-2 hour, add activated carbon decolorizing, filter, washing, drip salt forming agent solution, slowly be stirred to muddiness and go out crystalline substance, growing the grain, suction filtration, washing, vacuum-drying, obtains white or off-white color compound V, i.e. Cefodizime Sodium;
Synthetic route is:
Catalyzer described in step (1) is metal bromide or metal iodide;
Halogenated acid described in step (1) is trifluoroacetic acid;
Chemical compounds I in described step (1): compound ii: catalyzer: the mass ratio of halogenated acid is 1:0.41-0.47:0.01-0.03:1.8-4.7;
Organic solvent described in step (1) is acetone, and the described volume ratio containing acetone in the aqueous solution of organic solvent and water is 20:1-2;
The mass ratio of the compound III described in step (2) and compounds Ⅳ is 1:1.37-1.71;
Mixed solvent described in step (2) is the solvent that acetone and ethanol form, and its volume ratio is 1-3:1;
Organic bases described in step (2) is a kind of of pyridine or triethylamine or diethylamine or TERTIARY BUTYL AMINE or aniline or morpholine;
Salt forming agent described in step (2) is Sodium isooctanoate or sodium methylate or sodium-acetate, and the mass ratio of compound III and salt forming agent is 1:0.15-0.95.
CN201210317362.4A 2012-08-31 2012-08-31 Preparation method of cefodizime sodium Active CN102816173B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210317362.4A CN102816173B (en) 2012-08-31 2012-08-31 Preparation method of cefodizime sodium

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210317362.4A CN102816173B (en) 2012-08-31 2012-08-31 Preparation method of cefodizime sodium

Publications (2)

Publication Number Publication Date
CN102816173A CN102816173A (en) 2012-12-12
CN102816173B true CN102816173B (en) 2014-08-13

Family

ID=47300659

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210317362.4A Active CN102816173B (en) 2012-08-31 2012-08-31 Preparation method of cefodizime sodium

Country Status (1)

Country Link
CN (1) CN102816173B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101143870A (en) * 2006-09-12 2008-03-19 黄振华 Novel cephalosporin derivative
CN101239985A (en) * 2008-03-12 2008-08-13 齐鲁安替制药有限公司 Method for preparing cefodizime sodium

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101143870A (en) * 2006-09-12 2008-03-19 黄振华 Novel cephalosporin derivative
CN101239985A (en) * 2008-03-12 2008-08-13 齐鲁安替制药有限公司 Method for preparing cefodizime sodium

Also Published As

Publication number Publication date
CN102816173A (en) 2012-12-12

Similar Documents

Publication Publication Date Title
CN103539803B (en) A kind of method preparing ceftriaxone sodium
CN102372729B (en) Novel method for synthesizing cefoperazone sodium compound
CN101613359B (en) Method for synthesizing cefuroxime sodium
CN103467495A (en) Method for preparing cefixime compound
CN105131017B (en) A kind of preparation method of Method of cefcapene pivoxil hydrochloride
CN102030762B (en) Preparation method of cefprozil
CN101921284A (en) The preparation method of cefathiamidine
CN103757085B (en) Cefaclor and synthetic method thereof
CN109575048B (en) Preparation method of cefotaxime sodium
CN101337971A (en) Method for synthesizing antibiotic cefepime hydrochloride
CN101941982B (en) Novel preparation method of pharmaceutical ceforanide
CN103275103A (en) Method for preparing cefquinome sulfate
CN103319503A (en) Preparation method of cefdinir
CN105440054A (en) Process for preparing high-purity cefathiamidine
CN105017287B (en) A kind of preparation method of cephamycin intermediate
CN103044416A (en) Synthetic method of Carumonam sodium
CN102816173B (en) Preparation method of cefodizime sodium
CN110407857B (en) Preparation process of cefathiamidine
CN109912625B (en) Process method for reducing ceftazidime impurity H
CN104230956B (en) A kind of preparation method of cefoxitin
CN114409677B (en) Preparation method of high-purity cefotaxime acid
CN102199132A (en) Method for preparing 2-(2-amino-4-thiazole)-2(Z)-[[(tertbutyloxycarbonyl) methoxyl] imido] acetic acid and salt thereof
CN102942575B (en) Method for preparing cefodizime sodium
CN108586491B (en) Preparation method of cefetamet pivoxil hydrochloride
CN109956958B (en) A kind of synthetic method of 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP03 Change of name, title or address

Address after: 272073 Shandong city of Jining province high tech Zone Shixian Road No. 1688

Patentee after: AMICOGEN (CHINA) BIOPHARM CO.,LTD.

Address before: 272000 Shandong city of Jining province high tech Zone East Ring Road Lukang International Industrial Park

Patentee before: SHANDONG LUKANG RECORD PHARMACEUTICALS Co.,Ltd.

PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: A preparation method of cefodizime sodium

Effective date of registration: 20200730

Granted publication date: 20140813

Pledgee: Jining City branch of the China Co truction Bank Corp.

Pledgor: AMICOGEN (CHINA) BIOPHARM Co.,Ltd.

Registration number: Y2020980004549

PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20211115

Granted publication date: 20140813

Pledgee: Jining City branch of the China Co truction Bank Corp.

Pledgor: AMICOGEN (CHINA) BIOPHARM CO.,LTD.

Registration number: Y2020980004549

PC01 Cancellation of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: A preparation method of cefdizime sodium

Effective date of registration: 20211201

Granted publication date: 20140813

Pledgee: Jining City branch of the China Co truction Bank Corp.

Pledgor: AMICOGEN (CHINA) BIOPHARM CO.,LTD.

Registration number: Y2021980013624

PE01 Entry into force of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20221115

Granted publication date: 20140813

Pledgee: Jining City branch of the China Co truction Bank Corp.

Pledgor: AMICOGEN (CHINA) BIOPHARM CO.,LTD.

Registration number: Y2021980013624

PC01 Cancellation of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: A preparation method of cefodizime sodium

Effective date of registration: 20221117

Granted publication date: 20140813

Pledgee: Jining City branch of the China Co truction Bank Corp.

Pledgor: AMICOGEN (CHINA) BIOPHARM CO.,LTD.

Registration number: Y2022980022253

PE01 Entry into force of the registration of the contract for pledge of patent right